Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis
NCT02438410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13
Last updated 2022-05-04
Summary
To assess if infliximab drug levels in subjects with Ulcerative Colitis predict risk of colectomy rate. Additionally, the investigators will estimate an optimal day 4 infliximab level based on the study results.
Conditions
- Colitis, Ulcerative
- Inflammatory Bowel Disease
- IBD
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Darrell S Pardi, MD · Mayo Clinic
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-05-31
- Primary Completion
- 2019-12-04
- Completion
- 2019-12-04
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Blood Platelet Indices,Platelet Aggregation in the Activity of IBD Patients on Biological Treatment
NCT05406934 ·Status: UNKNOWN
-
Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
NCT03765450 ·Status: ACTIVE_NOT_RECRUITING
-
Hematological Indices and Fecal Calprotectin Predict Histological Remission in Ulcerative Colitis
NCT04818788 ·Status: UNKNOWN
-
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis
NCT00096655 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission
NCT03841942 ·Status: TERMINATED ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
NCT02065622 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients
NCT02129439 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis
NCT02852850 ·Status: UNKNOWN
-
Anemia in Inflammatory Bowel Disease
NCT02760940 ·Status: UNKNOWN ·Phase: PHASE4
-
A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis
NCT06786507 ·Status: NOT_YET_RECRUITING
-
Open-Label Adalimumab for Ulcerative Colitis Patients
NCT00421642 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study
NCT06998797 ·Status: NOT_YET_RECRUITING
-
Fecal Transplant for Ulcerative Colitis
NCT03948919 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis
NCT03178669 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis
NCT06269185 ·Status: COMPLETED
-
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
NCT00446849 ·Status: COMPLETED ·Phase: PHASE4
-
Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
NCT01346826 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Ischemic Colitis Compared to Other Diagnoses in Patients With Lower Gastrointestinal Bleeding
NCT01078324 ·Status: COMPLETED
-
Managing Infliximab Reinduction After Temporary Discontinuation of Drug
NCT02771457 ·Status: WITHDRAWN ·Phase: PHASE3
-
Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis
NCT03808506 ·Status: WITHDRAWN
-
Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis
NCT02922374 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
NCT03182166 ·Status: COMPLETED ·Phase: PHASE2
-
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
NCT00207688 ·Status: COMPLETED
-
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
NCT05931458 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Validity of Novel Non-invasive Inflammatory Markers for Monitoring of Patients With Ulcerative Colitis
NCT04670250 ·Status: UNKNOWN